Medicinova (MNOV) Amortization of Deferred Charges (2011 - 2022)
Medicinova (MNOV) posted quarterly Amortization of Deferred Charges of $45179.0 for Q1 2022, down 19.04% year-over-year from $55806.0 in Q1 2021, and down 19.04% quarter-over-quarter from $55806.0 in Q1 2021.
Medicinova (MNOV) Amortization of Deferred Charges (2011 - 2022) Analysis & Trends
Medicinova (MNOV) has reported Amortization of Deferred Charges for 3 consecutive years, with $45179.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Amortization of Deferred Charges fell 19.04% year-over-year to $45179.0; the TTM figure through Mar 2022 stood at $99947.0 (changed N/A YoY), while the FY2021 annual figure was $216640.0, up 3.06% from the prior year.
- Amortization of Deferred Charges retreated to $45179.0 in Q1 2022 per MNOV's latest filing, from $55806.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $55806.0 in Q1 2021 and bottomed at $45179.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 45,179.00 |
| Mar 31, 2022 | 45,179.00 |
| Mar 31, 2021 | 55,806.00 |
| Mar 31, 2021 | 55,806.00 |
| Sep 30, 2011 | -1,038.00 |
| Sep 30, 2011 | -1,038.00 |